Our team is comprised of a group of veteran scientists from world-renowned universities and institutes. Our revolutionary technical breakthrough in monoclonal antibody (mAb) development was made possible by our years of experience in cutting-edge biomedical research. With this novel mAb development platform, our scientists were the first ones to develop a panel of rabbit mAbs against anti-HIV Env. protein GP120 and discover the crystal structure of the rabbit monoclonal antibody.
The multidisciplinary expertise of our team in immunology, molecular biology, and cell biology has laid a solid foundation for Yurogen. Our passion is to translate bench work to bedside healthcare solutions by turning our proprietary antibody screening technology into premium monoclonal antibody products. The vision and coherent leadership of our team guides our long-term goal to become a leading supplier of premium antibodies for research, diagnostics, and future therapeutics.